{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:28:30Z","timestamp":1771036110766,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.amjmed.2012.08.007","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T02:06:04Z","timestamp":1358301964000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Alternate-day Dosing with Statins"],"prefix":"10.1016","volume":"126","author":[{"given":"Frank I.","family":"Marcus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Baumgarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Paul E.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2012.08.007_bib1","first-page":"616","article-title":"Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor","volume":"40","author":"Stern","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2012.08.007_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0009-9236(96)90218-0","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects","volume":"60","author":"Cilla","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2012.08.007_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/j.1552-4604.1997.tb04305.x","article-title":"Rate of low-density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment","volume":"37","author":"Stern","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2012.08.007_bib4","first-page":"1769","article-title":"ESC EAS Guidelines for the management of dyslipidaemais","volume":"32","author":"Zeljko","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2012.08.007_bib5","doi-asserted-by":"crossref","first-page":"3J","DOI":"10.1016\/S0002-9149(98)00423-8","article-title":"Current and future treatment of hyperlipidemia: the role of statins","volume":"82","author":"Farnier","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2012.08.007_bib6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archinternmed.2008.552","article-title":"Continuation of statin treatment and all-cause mortality","volume":"169","author":"Shalev","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib8","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2012.08.007_bib9","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention","volume":"170","author":"Ray","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0025-6196(11)60544-2","article-title":"Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease","volume":"84","author":"Karalis","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2012.08.007_bib11","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2012.08.007_bib12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus, and hypercholesterolemia: the Vytal Study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2012.08.007_bib13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0002-9149(99)00030-2","article-title":"Effectiveness and safety of alternate day simvastatin and fenofibrate on mixed hyperlipidemia","volume":"83","author":"Kayikcioglu","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2012.08.007_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1345\/aph.10164","article-title":"Alternate-day dosing of HMG-CoA reductase inhibiters for cholesterol reduction","volume":"35","author":"Metz","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2012.08.007_bib15","first-page":"297","article-title":"Effect and safety of atorvastatin 10 mg every other day in hypercholesterolemia","volume":"85","author":"Piamsumboun","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.amjmed.2012.08.007_bib16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0002-8703(02)00140-0","article-title":"Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia?","volume":"144","author":"Matalka","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2012.08.007_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/107424840300800205","article-title":"Efficacy of alternate-day dosing versus daily dosing of atorvastatin","volume":"8","author":"Jafari","year":"2003","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.amjmed.2012.08.007_bib18","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1345\/aph.1H124","article-title":"Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia","volume":"40","author":"Wongwiwatthananukit","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2012.08.007_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00592-006-0216-4","article-title":"Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia","volume":"43","author":"Ferrer-Garcia","year":"2006","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.amjmed.2012.08.007_bib20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1345\/aph.1M571","article-title":"Alternate-day statin therapy for the treatment of hyperlipidemia","volume":"40","author":"Reindl","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2012.08.007_bib21","first-page":"407","article-title":"The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels","volume":"8","author":"Keles","year":"2008","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.amjmed.2012.08.007_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cca.2011.09.006","article-title":"Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers","volume":"413","author":"Li","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjmed.2012.08.007_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11883-010-0120-9","article-title":"Evidence-based management of statin myopathy","volume":"12","author":"Harper","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjmed.2012.08.007_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2146\/ajhp100700","article-title":"Strategies to preserve the use of statins in patients with previous muscular adverse effects","volume":"69","author":"Reinhart","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.amjmed.2012.08.007_bib25","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2012.489","article-title":"Use of administrative data to estimate the incidence of statin-related rhabdomyolysis","volume":"307","author":"Floyd","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2012.08.007_bib26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2012.08.007_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2012.08.007_bib30","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2012.08.007_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/vhrm.1.1.29.58937","article-title":"Ongoing clinical trials of the pleiotropic effects of statins","volume":"1","author":"Davignon","year":"2005","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amjmed.2012.08.007_bib32","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1253\/circj.CJ-10-0707","article-title":"Effect of preoperative statin therapy on postoperative atrial fibrillation in cardiac surgery","volume":"74","author":"Takagi","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2012.08.007_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins: basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2012.08.007_bib34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.athoracsur.2008.01.040","article-title":"Dose-related effect of statins on atrial fibrillation after cardiac surgery","volume":"85","author":"Kourliouros","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.amjmed.2012.08.007_bib35","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/eurheartj\/ehs005","article-title":"Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials","volume":"33","author":"Rahimi","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2012.08.007_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.111.081059","article-title":"Statins and the risk of cancer after heart transplantation","volume":"126","author":"Fr\u00f6hlich","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2012.08.007_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7326\/0003-4819-150-4-200902170-00005","article-title":"Comparing impact and cost effectiveness of primary prevention strategies for lipid lowering","volume":"150","author":"Pletcher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2012.08.007_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2710.1997.tb00021.x","article-title":"Prescriptions of statins: cost implications of evidence-based treatment applied to a health authority population","volume":"22","author":"Bradshaw","year":"1997","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.amjmed.2012.08.007_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/eurheartj\/ehq297","article-title":"Strategies to improve drug adherence","volume":"32","author":"Laufs","year":"2011","journal-title":"Eur Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934312007243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934312007243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:59:36Z","timestamp":1757581176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934312007243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0002934312007243"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternate-day Dosing with Statins","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}